Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo shows promise against tough head and neck cancer

NCT ID NCT06959108

Recruiting now Disease control Sponsor: Groupe Oncologie Radiotherapie Tete et Cou Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an immunotherapy drug (pucotenlimab) to a targeted therapy (MRG003) before standard chemoradiation can shrink tumors more effectively in people with advanced head and neck cancer. About 106 adults aged 18-75 with locally advanced squamous cell carcinoma of the head and neck will take part. Half will get MRG003 alone, and half will get MRG003 plus pucotenlimab, followed by chemoradiation and then additional pucotenlimab. The main goal is to see which group has a better tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact